the keynote-001 trial: a breakthrough for pembrolizumab
Published 6 years ago • 473 plays • Length 3:07Download video MP4
Download video MP3
Similar videos
-
1:48
results of keynote-024 trial of pembrolizumab in nsclc
-
1:41
pembrolizumab improves 5-year survival in advanced nsclc in keynote-001
-
1:15
introduction to keynote-100 trial of pembrolizumab in advanced recurrent ovarian cancer
-
1:13
a new standard of care for advanced lung cancer: what’s next for pembrolizumab?
-
6:40
keynote-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer
-
5:16
keynote-001: five year data from the phase ib trial studying pembrolizumab as treatment for ansclc
-
2:09
keynote-240: pembrolizumab in advanced hcc
-
0:51
pembrolizumab increases long-term survival in patients with advanced nsclc
-
1:01
dr. garon on the keynote-001 study in nsclc
-
2:25
keynote-224: second-line pembrolizumab for advanced hepatocellular carcinoma
-
1:02
pembrolizumab monotherapy for nsclc: keynote-024 update
-
2:53
keynote-407: pembrolizumab plus chemo improves os and pfs in nsclc
-
1:14
keynote-042: revolutionizing lung cancer treatment with pembrolizumab monotherapy
-
1:25
a real-world analysis on pembro monotherapy versus pembro chemotherapy for never-smoking nsclc
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
2:54
pembrolizumab or egfr tyrosine kinase inhibitors in nsclc?
-
3:35
keynote-006: the efficacy of ipilimumab after pembrolizumab in patients with advanced melanoma
-
1:23
how effective is pembrolizumab in cisplatin-ineligible bladder cancer? results from keynote-052
-
2:02
keynote-189: chemo plus pembrolizumab for nsclc